drugset / Trial / NCT04649697

Rebamipide (Regular & Nanoparticulated) vs. Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients

NCT04649697

Phase 3 Unknown 39 enrolled Cairo University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this intervention study is to compare the effect of topical Rebamipide (regular and nanoparticulated) to topical Clobetasol propionate in management of Methotrexate induced oral mucositis in patients with rheumatoid arthritis.

Timeline

Start
2020-12-01
Primary completion
2023-12-30
Completion
2023-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Rebamipide Small molecule
Comparator clobetasol propionate Small molecule

Indications